Mavoglurant

Overview
Catalog #	bs-6678c-10mg-solid
Product Name	Mavoglurant
Specifications
Storage Buffer	Powder
Storage Condition	Store in dry, dark place at -20C for 1 year.
Target
Product Information	Molecular Weight: 313.39 Formula: C19 H23 N O3 CAS Number: 543906-09-8 InChi Key: ZFPZEYHRWGMJCV-ZHALLVOQSA-N InChi: InChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1 Smiles: CC1C=CC=C(C=1)C#C[C@]1(O)CCC[C@@H]2[C@H]1CCN2C(=O)OC Purity: 98.0 Solubility: Soluble in DMSO, not in water Appearance: Solid Power. Shelf Life: 1.0 years
Description	Mavoglurant, aslo known as AFQ056, is an experimental drug candidate for the treatment of fragile X syndrome. Mavoglurant exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5). Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results. Currently Novartis is conducting a clinical trial with this drug on obsessive compulsive disorder.